Company news
Solvonis Therapeutics Plc (LSE:SVNS) news
Solvonis Therapeutics Plc news releases on 6ix. Latest, Oct 6, 2026: Investor Webinar – 15 October 2026
Press releases & updates
Investor Webinar – 15 October 2026
October 6, 2026
Notification of Admission of Shares and TVR
September 30, 2026
Unaudited interim results
September 30, 2026
New Analysis Identifies Major AUD Breakthrough
September 29, 2026
Vital Patent milestone achieved– SVN 114
September 3, 2026
Solvonis Raises £1.3 Million
August 25, 2026
Solvonis to Present at WTR Conference
August 11, 2026
SVN-015 Advances into Further NIDA-Funded Studies
August 6, 2026
Research Coverage Initiation
July 13, 2026
Solvonis Announces Positive SVN-002 Bridging Data
June 23, 2026
Announces Positive Bridging Data Supporting
June 22, 2026
Solvonis Announces Result of AGM
June 19, 2026
CSO Speaks at National Research Meeting
May 5, 2026
Appointment of Water Tower Research
April 22, 2026
US CNS Executive Order
April 20, 2026
Granted U.S. Patent from PTSD Discovery Programme
April 8, 2026
SVN-114 selected for PTSD discovery programme
March 10, 2026
Expansion of SVN-015 into depression
January 28, 2026
US Patent allowance for PTSD discovery programme
January 7, 2026
Research and Development Update – Q4 2025
December 22, 2025
SVN-015 accepted into US NIDA funded programme
December 3, 2025
Total Voting Rights
October 31, 2025
Appoints global biopharma leader Paul Carter
October 27, 2025
Raises £1.25 Million to Accelerate Programmes
October 16, 2025
Half-year Report
September 30, 2025
Solvonis secures exclusive CNS collaboration
August 28, 2025
Media Coverage: Small Cap Idea profile
August 13, 2025
SVN-SDN-14 PTSD - Positive pre-clinical results
August 12, 2025
Translational Bridging Studies
July 22, 2025
Exercise of warrants
July 18, 2025
Solvonis Chair to speak at Lucid Capital Markets
July 14, 2025
£1m subscription to accelerate AI drug discovery
July 11, 2025
Holding(s) in Company
July 8, 2025
AGM Statement
June 27, 2025
Initiation of Research Coverage
June 26, 2025
Allowance of U.S. patent covering AI-supported CNS
June 23, 2025
Initiation of AI supported CNS drug discovery
June 11, 2025
Synthesis of development candidate for SVN-SDN-014
June 5, 2025
Notice of Annual General Meeting
June 3, 2025
Presentation at Mello2025
May 29, 2025
Completion of the acquisition of Awakn
May 28, 2025
Publication of a Prospectus
May 21, 2025
Result of placing
May 16, 2025
Proposed equity fundraising via ABB
May 15, 2025
Result of General Meeting
April 28, 2025
Proposed acquisition of Awakn approved
April 23, 2025
Final Results for the year ended 31 December 2024
April 16, 2025
Posting of Circular and Notice of General Meeting
April 10, 2025
Engagement of PharmaVentures
April 4, 2025
Positive progress on European Patent Application
March 26, 2025